NCT03262454 (Atezolizumab) is a Phase 2 clinical trial of Atezolizumab in Small Cell Lung Cancer Recurrent, sponsored by National Cancer Center, Korea.

Who is sponsoring NCT03262454?

NCT03262454 is sponsored by National Cancer Center, Korea.

What drugs are being tested in NCT03262454?

Interventions in NCT03262454: Atezolizumab.

What condition does NCT03262454 study?

NCT03262454 studies Small Cell Lung Cancer Recurrent.

Is NCT03262454 still recruiting?

NCT03262454 is currently status unknown. Last updated 6 April 2022.

Last reviewed 2022-04-06 · How we verify

NCT03262454: Atezolizumab

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC

Status unknown Phase 2 Last updated 6 April 2022

What this trial tests

Phase 2 trial testing Atezolizumab in Small Cell Lung Cancer Recurrent in 35 participants. Status unknown.

Timeline

22 January 2018

Primary endpoint
23 February 2023

31 July 2024

Quick facts

Lead sponsor	National Cancer Center, Korea
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	22 January 2018
Primary completion	23 February 2023
Estimated completion	31 July 2024
Sites	1 location across South Korea

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Small Cell Lung Cancer Recurrent — all drugs for Small Cell Lung Cancer Recurrent →

Sponsor

National Cancer Center, Korea

Who can join

18 and older, any sex, with Small Cell Lung Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators hypothesized that local radiation therapy can enhance the effect of anti-PD-L1 monoclonal antibody through priming T-cell effector function against cancer cells. Described as above, The investigators concluded that modest dose of radiation to local site prior to immunotherapy is the best to enhance T-cell-mediated immunity. Accordingly, The investigators will investigate the combining effect of hypofractionated-sublethal dose of radiation therapy followed by anti-PD-L1 monoclonal antibody, atezolizumab, for SCLC patients who are recurrent or refractory for initial platinum-based chemotherapy

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Ai L, Chen J, Yan H, He Q, et al · · 2020 · cited 149× · PMID 32982171 · DOI 10.2147/dddt.s267433
Radiation-induced tumor immune microenvironments and potential targets for combination therapy.
Guo S, Yao Y, Tang Y, Xin Z, et al · · 2023 · cited 136× · PMID 37208386 · DOI 10.1038/s41392-023-01462-z
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, et al · · 2020 · cited 78× · PMID 33322522 · DOI 10.3390/cancers12123729
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Tian Y, Zhai X, Han A, Zhu H, et al · · 2019 · cited 76× · PMID 31253167 · DOI 10.1186/s13045-019-0753-2
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
Pavan A, Attili I, Pasello G, Guarneri V, et al · · 2019 · cited 74× · PMID 31383005 · DOI 10.1186/s40425-019-0690-1
Combination therapy: Future directions of immunotherapy in small cell lung cancer.
Huang W, Chen JJ, Xing R, Zeng YC. · · 2021 · cited 42× · PMID 33065386 · DOI 10.1016/j.tranon.2020.100889
Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure.
Chen P, Kuang P, Wang L, Li W, et al · · 2020 · cited 24× · PMID 32676338 · DOI 10.21037/tlcr-19-547
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.
Regzedmaa O, Zhang H, Liu H, Chen J. · · 2019 · cited 23× · PMID 31354294 · DOI 10.2147/ott.s204577

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Small Cell Lung Cancer Recurrent

Currently open trials in the same condition.

NCT06258642 — Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC · NA · recruiting

Other National Cancer Center, Korea trials

Trials by the same sponsor.

NCT07399561 — Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy · NA · not yet recruiting
NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03262454 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
Last refreshed: 6 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03262454.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing